Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard
hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial
Hyperplasia or well to moderately differentiated endometrial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health